Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease

Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.

The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.

Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.


More from Teprotumumab News:

Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED

FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED


More from Teprotumumab Research:

Teprotumumab for the Treatment of Active Thyroid Eye Disease

(Authors: Raymond S. Douglas, George J. Kahaly et. al.)


Teprotumumab in the Treatment of Active TED: A Focus on Proptosis

(Author: Raymond S. Douglas)

Teprotumumab Significantly Improves Proptosis In Thyroid Eye Disease